4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0002034668-25-000010
Chief Financial Officer sold 18,400 shares at an average $18.54 ($341,074)
- Chief Financial Officer acquired 18,400 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hyep Ivan · Chief Financial Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-11-21 | Exercise or conversion : show line 1 in the form 10b5-1 | +605 | $3.79 | $2,293 | 145,960 | D |
| 2025-11-21 | Sale : show line 2 in the form 10b5-1 | −605 | $18.15 | $10,981 | 145,355 | D |
| 2025-11-24 | Exercise or conversion : show line 3 in the form 10b5-1 | +17,795 | $3.79 | $67,439 | 163,150 | D |
| 2025-11-24 | Sale : show line 4 in the form 10b5-1 | −17,795 | $18.55 | $330,094 | 145,355 | D |
| Open-market sales · 18,400 sh · avg $18.54 · $341,074 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-11-21 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −605 | 115,979 | D |
| 2025-11-24 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) | −17,795 | 98,184 | D |
Loading xslF345X05/wk-form4_1764114131.xml…